{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:10Z","timestamp":1792089430237,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.micpath.2025.108170","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T09:15:59Z","timestamp":1762766159000},"page":"108170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunological characteristics of inactivated vaccines after vaccination and short-term concentrated BA.4\/5 exposure: A prospective cohort study in Henan, China"],"prefix":"10.1016","volume":"210","author":[{"given":"Kai","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2025.108170_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.micpath.2025.108170_bib2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2025.108170_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40249-021-00915-3","article-title":"Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.micpath.2025.108170_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.addr.2020.12.006","article-title":"Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection","volume":"169","author":"Batty","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.micpath.2025.108170_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-012621-102252","article-title":"COVID-19 vaccines: adenoviral vectors","volume":"73","author":"Jacob-Dolan","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658519","article-title":"Potential therapeutic targets and vaccine development for SARS-CoV-2\/COVID-19 pandemic management: a review on the recent update","volume":"12","author":"Anand","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2025.108170_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-med-042420-113212","article-title":"Whole inactivated virus and protein-based COVID-19 vaccines","volume":"73","author":"Hotez","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib8","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijid.2022.03.028","article-title":"Waning COVID-19 vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study","volume":"119","author":"Suah","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108170_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108170_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(22)00732-0","article-title":"Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study","volume":"23","author":"Tsang","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108170_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2025.108170_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108170_bib14","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2025.108170_bib15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S1473-3099(22)00420-0","article-title":"Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Mallory","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108170_bib16","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108170_bib17","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2025.108170_bib18","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101680","article-title":"Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial","volume":"54","author":"Zhang","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.micpath.2025.108170_bib21","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib22","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib24","article-title":"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 gamma variant transmission in Manaus, Brazil: a test-negative case-control study","volume":"1","author":"Hitchings","year":"2021","journal-title":"Lancet Reg. Health Am."},{"key":"10.1016\/j.micpath.2025.108170_bib25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib26","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(22)00143-8","article-title":"Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden","volume":"22","author":"Nordstr\u00f6m","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108170_bib29","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1443","article-title":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang Province, China, January-March 2020: retrospective cohort study","author":"Zheng","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.micpath.2025.108170_bib31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12250-021-00360-4","article-title":"Sustainability of SARS-CoV-2 induced humoral immune responses in COVID-19 patients from hospitalization to convalescence over six months","volume":"36","author":"Zheng","year":"2021","journal-title":"Virol. Sin."},{"key":"10.1016\/j.micpath.2025.108170_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.micpath.2025.108170_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib34","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1080\/22221751.2022.2065936","article-title":"COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia","volume":"11","author":"Yang","year":"2022","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.micpath.2025.108170_bib35","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.micpath.2025.108170_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.micpath.2025.108170_bib37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(22)00126-6","article-title":"Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study","volume":"10","author":"Huang","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.micpath.2025.108170_bib38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/23744235.2021.1924397","article-title":"Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments","volume":"53","author":"Yong","year":"2021","journal-title":"Inf. Disp."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025008952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025008952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:27:02Z","timestamp":1773872822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401025008952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"alternative-id":["S0882401025008952"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.108170","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological characteristics of inactivated vaccines after vaccination and short-term concentrated BA.4\/5 exposure: A prospective cohort study in Henan, China","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.108170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108170"}}